Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Chong

Gastroenterology Delray Beach, FL Medical Doctor

NPI 1538130828 CMS profile 205685

4675 Linton Blvd, Suite 202, Delray Beach, FL 33445

Open in the dashboard

General payments

$14,939

761 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Chong of Delray Beach, FL is reported in the CMS Open Payments database as having received $14,939 across 761 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,993 115
2024 General $1,945 89
2023 General $2,349 112
2022 General $2,423 125
2021 General $2,294 138
2020 General $1,255 75
2019 General $1,681 107

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Chong
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to James Chong were reported at $2,993. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year James Chong Gastroenterology median Middle half National median
2019 $1,681 $417 $126–$1,100 $163
2020 $1,255 $224 $74–$624 $114
2021 $2,294 $352 $106–$1,054 $132
2022 $2,423 $448 $129–$1,270 $149
2023 $2,349 $533 $150–$1,390 $160
2024 $1,945 $605 $160–$1,606 $164
2025 $2,993 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $4,155 184 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,367 91 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,360 57 payments
  4. Janssen Biotech, Inc. $956 50 payments
  5. Celgene Corporation $945 96 payments
  6. QOL Medical, LLC $676 33 payments
  7. Merck Sharp & Dohme Corporation $453 22 payments
  8. Medtronic, Inc. $322 3 payments
  9. Cumberland Pharmaceuticals, Inc. $316 15 payments
  10. Phathom Pharmaceuticals, Inc. $309 6 payments
  11. Other $4,080 204 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,611 743 payments
  2. Education $328 18 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,868 81 payments
  2. XIFAXAN $1,405 94 payments
  3. ENTYVIO $1,050 41 payments
  4. ZEPOSIA $918 95 payments
  5. SKYRIZI Immunology $816 35 payments
  6. SKYRIZI Immunology $682 28 payments
  7. CREON $679 36 payments
  8. STELARA $672 37 payments
  9. LINZESS $585 35 payments
  10. HUMIRA $583 34 payments
  11. Other $7,605 371 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

3,681

Median for Gastroenterology: 569

Drug cost

$1,134,147

Median for Gastroenterology: $104,976

Branded share of claims

13.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gattex Teduglutide Brand 12 $550,710
Humira(Cf) Pen Adalimumab Brand 13 $174,974
Humira Pen Adalimumab Brand 12 $80,925
Linzess Linaclotide Brand 89 $79,755
Mesalamine Generic 64 $35,476
Viberzi Eluxadoline Brand 25 $33,009
Dexlansoprazole Dr Dexlansoprazole Brand 49 $21,408
Pantoprazole Sodium Generic 1,200 $19,536
Colestipol Hcl Generic 178 $19,346
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 94 $14,994

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$708,166

Of which drugs: $387,577

Medicare patients

1,360

Average age 78

Services billed

26,784

847 women, 513 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 53%
Osteoporosis 36%
Diabetes 31%
Chronic kidney disease 29%
Depression 28%
Cancer 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 39 17,100 $297,232

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
$255 — 17,100
VOQUEZNA
$179 — —
SKYRIZI
$172 — —
RINVOQ
$165 — —
ZEPOSIA
$132 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

761 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record